Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX).

Aldeyra Stock Drops Significantly as FDA Rejects Reproxalap NDA, Citing Efficacy and Methodological Issues

On April 3, 2025, Aldeyra “. . . announce[d] that it had received a Complete Response Letter . . . from the U.S. Food & Drug Administration . . . regarding the Company’s resubmitted New Drug Application . . . for reproxalap, an investigational drug candidate, for the treatment of dry eye disease.”

The Company reported that the FDA’s letter “. . . stated that the NDA ‘failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes’ and that ‘at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye’ should be conducted.”

Aldeyra reported that “[t]he letter identified concerns with the data from the trial submitted to the NDA that may have affected interpretation of the results, which the FDA stated may be related to methodological issues, including a difference in baseline scores across treatment arms.”

On this news, Aldeyra’s stock price dropped more than 73% from a closing price of $5.32 on April 2, 2025 to $1.42 per share at the close of trading on April 3, 2025. 

Investors of Aldeyra Stock May Have Legal Claims 

Aldeyra shareholders are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or send us a message to contact an attorney to discuss the securities investigation and receive a free, no-obligation evaluation of potential legal claims.

Aldeyra investors can also contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected].

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Ibotta, Inc. (“Ibotta”) (NYSE:IBTA).

Class Action Filed Against Ibotta

On April 17, 2025, a class action complaint alleging violations of federal securities laws was filed against Ibotta in United States District Court, District of Colorado (Case No. 1:25-cv-01213), on behalf of those who purchased or otherwise acquired publicly-traded Ibotta securities pursuant and/or traceable to the registration statement and related prospectus (the “Registration Statement”) issued in connection with Ibotta’s April 18, 2024 initial public offering (“IPO”).

The securities class action lawsuit seeks to recover compensable damages caused by the Ibotta Defendant’s alleged violations of the federal securities laws under the Securities Act of 1933.

The Registration Statement, according to the complaint, “. . . was negligently prepared and, as a result, contained untrue statements of material facts or omitted to state other facts necessary to make the statements made not misleading, and was not prepared in accordance with the rules and regulations governing its preparation.”

To review a copy of the complaint, please click Ibotta Class Action Complaint.

Ibotta Investors May Have Legal Claims 

Investors who acquired Ibotta securities pursuant and/or traceable to the company’s Registration Statement issued in connection with Ibotta’s IPO are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or send us a message to contact an attorney to discuss the securities investigation and receive a free, no-obligation evaluation of potential legal claims.

Ibotta shareholders can also contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected].

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas BioPharma”) (NASDAQ:ZBIO).

Class Action Filed Against Zenas BioPharma 

On April 16, 2025, a class action complaint alleging violations of federal securities laws was filed against Zenas BioPharma in United States District Court, District of Massachusetts (Case No. 1:25-cv-10988), on behalf of investors who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement and related prospectus (the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO”). 

To review a copy of the complaint, please click ZBIO Class Action Complaint.

Zenas BioPharma Investors May Have Legal Claims 

Investors who acquired Zenas BioPharma securities pursuant and/or traceable to the company’s IPO are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or send us a message to contact an attorney to discuss the securities investigation and receive a free, no-obligation evaluation of potential legal claims.

Zenas BioPharma shareholders can also contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected].

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]